Clinical trial
Gemcitabine With or Without Dalteparin in Treating Patients With Locally…
NCT00462852 · Hull University Teaching Hospitals NHS Trust, Other · Completed
Key facts
| NCT number | NCT00462852 |
|---|---|
| Title | Gemcitabine With or Without Dalteparin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer |
| Official title | A Phase II Randomized Study of Chemo-Anticoagulation (Gemcitabine-Dalteparin) Versus Chemotherapy Alone (Gemcitabine) for Locally Advanced and Metastatic Pancreatic Adenocarcinoma [FRAGEM] |
| Lead sponsor | Hull University Teaching Hospitals NHS Trust, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer, Thromboembolism |
| Intervention type | Drug, Other |
| Interventions | dalteparin, gemcitabine hydrochloride, diagnostic laboratory biomarker analysis |
| Enrollment | 120 |
| Start date | Apr 1, 2003 |
| Completion | Nov 1, 2011 |
| First posted | Apr 19, 2007 |
| Last update posted | Aug 12, 2013 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: